We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...

Luckily, most streaming services these days offer a sneak peek via free trials into their cache of goodies. So whatever you’re looking to watch in 2025, these nine free trials are a great way to ...

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

Investing.com -- GSK (LON ... and vaccines are in clinical development, with 19 in late-stage trials or under regulatory review. Five major product approvals are expected in 2025, including Blenrep ...

The presentation was sent to our distribution list by email, and you can also find it on gsk.com ... will differentiate based on clinical data. And the market research that we have in these ...

GSK (LON:GSK) has raised its long-term revenue outlook, now expecting sales to exceed £40 billion by 2031, up from £38 billion. The revision reflects confidence in its expanding specialty ...

GSK has recently launched a phase 3 trial, Dreamm-10 ... peak sales from Nucala and the near-market long-acting IL-5 drug depemokimab, will help boost the contribution of GSK's specialty medicines ...

HL Building Blocks Build your own portfolio with HL's specially designed fund range Wealth Shortlist A selection of funds we've researched and chosen for their long-term potential ...

Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More. GSK (LSE:GSK) shares ended 2024 on a sour ...

GSK plans to buy back $2.50 billion in shares ... the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not ...